OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial (CROSBI ID 178381)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Aurora, S.K. ; Dodick, D.W. ; Turkel, C.C. ; DeGryse, R.E. ; Silberstein, S.D. ; Lipton, R.B. ; Diener, H.C. ; Brin, M.F. ; PREEMPT 1 Chronic Migraine Study Group ; Becker, W.J. ; Blumenfeld, A. ; Cutrer, F.M. ; Gendolla, A. ; Lay, C. ; Martin, V. ; Relja, Maja ; Schim, J.D. ; Smith, T.R. ; Ward, T.W. ; Winner, P.
engleski
OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
chronic migraine; cnabotulinumtoxinA; prophylaxis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti
